{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:45:18Z","timestamp":1791251118074,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"Background<\/jats:title>Despite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel therapies are urgently needed. As the anti-CD20 antibody rituximab and the CD19-targeting antibody tafasitamab share distinct modes of actions, we investigated if dual-targeting of aggressive lymphoma B-cells by combining rituximab and tafasitamab might increase cytotoxic effects.<\/jats:p><\/jats:sec>Methods<\/jats:title>Antibody single and combination efficacy was determined investigating different modes of action including direct cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) in in vitro<\/jats:italic> and in vivo<\/jats:italic> models of aggressive B-cell lymphoma comprising diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).<\/jats:p><\/jats:sec>Results<\/jats:title>Three different sensitivity profiles to antibody monotherapy or combination treatment were observed in in vitro<\/jats:italic> models: while 1\/11 cell lines was primarily sensitive to tafasitamab and 2\/11 to rituximab, the combination resulted in enhanced cell death in 8\/11 cell lines in at least one mode of action. Treatment with either antibody or the combination resulted in decreased expression of the oncogenic transcription factor MYC and inhibition of AKT signaling, which mirrored the cell line-specific sensitivities to direct cytotoxicity. At last, the combination resulted in a synergistic survival benefit in a PBMC-humanized Ramos NOD\/SCID mouse model.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>This study demonstrates that the combination of tafasitamab and rituximab improves efficacy compared to single-agent treatments in models of aggressive B-cell lymphoma in vitro<\/jats:italic> and in vivo<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1220558","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T21:36:05Z","timestamp":1690839365000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Maria","family":"Patra-Kneuer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaomei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Augsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myroslav","family":"Zapukhlyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ilieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Landgraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Mangelberger-Eberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasra","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Berning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin S.","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Khandanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Horna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Schanzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Steidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Endell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Heitm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.21037\/aol.2018.12.02","article-title":"Aggressive B-cell lymphomas\u2014from morphology to molecular pathogenesis","volume":"3","author":"Chen","year":"2019","journal-title":"Ann Lymphoma"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.07.013","article-title":"Burkitt lymphoma- a rare but challenging lymphoma","volume":"31","author":"Casulo","year":"2018","journal-title":"Best Pract Res Cl Ha"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"B9","unstructured":"Rituxan (Rituximab) Label2012"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-chop failure\u2014What to do","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international scholar-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"Chop-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the mabthera international trial (Mint) group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.21338","article-title":"Cd19 as an attractive target for antibody-based therapy","volume":"4","author":"Hammer","year":"2012","journal-title":"Mabs-Austin"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000442170","article-title":"Cd19-targeted car T cells: A new tool in the fight against B cell malignancies","volume":"38","author":"Miller","year":"2015","journal-title":"Oncol Res Treat"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177469","article-title":"Diffuse large B-cell lymphoma: reduced cd20 expression is associated with an inferior survival","volume":"113","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02307.x","article-title":"Comparison of Cd20 Expression in B-Cell Lymphoma between Newly Diagnosed, Untreated Cases and Those after Rituximab Treatment","volume":"103","author":"Miyoshi","year":"2012","journal-title":"Cancer Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8243","article-title":"Comparison of the algorithms classifying the abc and gcb subtypes in diffuse large B-cell lymphoma","volume":"15","author":"Boltezar","year":"2018","journal-title":"Oncol Lett"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1182\/blood-2019-129600","article-title":"Comparative assessment of surface cd19 and cd20 expression on B-cell lymphomas from clinical biopsies: implications for targeted therapies","volume":"134","author":"Horna","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-08-2268","article-title":"Potent in vitro and in vivo Activity of an Fc-Engineered Anti-Cd19 Monoclonal Antibody against Lymphoma and Leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-229039","article-title":"Cd19 targeting of chronic lymphocytic leukemia with a novel fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2003.01702.x","article-title":"Immunohistochemical analysis of B-cell lymphoma using tissue microarrays identifies particular phenotypic profiles of B-cell lymphomas","volume":"43","author":"Zettl","year":"2003","journal-title":"Histopathology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758599","article-title":"Sensitivity to pi3k and akt inhibitors is mediated by divergent molecular mechanisms in subtypes of dlbcl","volume":"130","author":"Erdmann","year":"2017","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718775","article-title":"B-cell receptor-driven malt1 activity regulates myc signaling in mantle cell lymphoma","volume":"129","author":"Dai","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3317","article-title":"Hisat: A fast spliced aligner with low memory requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat Methods"},{"key":"B26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"Rsem: accurate transcript quantification from rna-seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf"},{"key":"B27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate - a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"P Natl Acad Sci USA"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (Msigdb) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"B30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.0105-2896.2006.00373.x","article-title":"A library of gene expression signatures to illuminate normal and pathological lymphoid biology","volume":"210","author":"Shaffer","year":"2006","journal-title":"Immunol Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1038\/s41467-019-12713-5","article-title":"Dissection of Gene Expression Datasets into Clinically Relevant Interaction Signatures via High-Dimensional Correlation Maximization","volume":"10","author":"Grau","year":"2019","journal-title":"Nat Commun"},{"key":"B32","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittel-Forsch"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1038\/s41598-020-61923-1","article-title":"A critical evaluation of methods to interpret drug combinations","volume":"10","author":"Twarog","year":"2020","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7493-1_17","article-title":"Methods for high-throughput drug combination screening and synergy scoring","volume":"1711","author":"He","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btx162","article-title":"Synergyfinder: A web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"Synergyfinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom Proteom Bioinform"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/his.13287","article-title":"Myc protein dysregulation is driven by bcr-pi3k signalling in diffuse large B-cell lymphoma","volume":"71","author":"Wang","year":"2017","journal-title":"Histopathology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237537","article-title":"Rituximab inhibits B-cell receptor signaling","volume":"115","author":"Kheirallah","year":"2010","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840070628","article-title":"Multivariate survival analysis using cox\u2019s regression model","volume":"7","author":"Christensen","year":"1987","journal-title":"Hepatology"},{"key":"B40","volume-title":"Analysis of Survival Data","author":"Cox","year":"1984"},{"key":"B41","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Terry","year":"2000"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-mind): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B43","unstructured":"2021"},{"key":"B44","unstructured":"Fda Grants Accelerated Approval to Tafasitamab-Cxix for Diffuse Large B-Cell Lymphoma2020"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159955","article-title":"Blocking the cd47-sirpa axis enhances tafasitamab-mediated phagocytosis","volume":"140","author":"Biedermann","year":"2022","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879015","article-title":"Pd-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0052-1","article-title":"Nk cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.3390\/cancers12113429","article-title":"Genetic variants of the nkg2c\/hla-E receptor-ligand axis are determinants of progression-free survival and therapy outcome in aggressive B-cell lymphoma","volume":"12","author":"Wagner","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-594507","article-title":"Essential role of irf4 and myc signaling for survival of anaplastic large cell lymphoma","volume":"125","author":"Weilemann","year":"2015","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.575","article-title":"Understanding myc-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"2013","author":"Ott","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The myc oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2231","article-title":"Reflecting on 25 years with myc","volume":"8","author":"Meyer","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102089","article-title":"Rituximab and obinutuzumab differentially hijack the B cell receptor and notch1 signaling pathways","volume":"24","author":"Edelmann","year":"2021","journal-title":"iScience"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.05.008","article-title":"Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia","volume":"28","author":"Shojaee","year":"2015","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.111","article-title":"Autoimmunity checkpoints as therapeutic targets in B cell malignancies","volume":"18","author":"Muschen","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08857.x","article-title":"A Glycoengineered Anti-Cd19 Antibody with Potent Antibody-Dependent Cellular Cytotoxicity Activity in vitro and Lymphoma Growth Inhibition in vivo","volume":"155","author":"Ward","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1220558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T21:36:12Z","timestamp":1690839372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1220558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2023.1220558"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1220558","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"article-number":"1220558"}}